| 13th May 2016 7:00 am |
RNS |
Enrollment completion of Phase III fruquintinib |
| 29th Apr 2016 7:00 am |
RNS |
Total Voting Rights |
| 27th Apr 2016 1:12 pm |
RNS |
Results of Annual General Meeting |
| 13th Apr 2016 4:23 pm |
RNS |
Exercise of Overallotment Option |
| 31st Mar 2016 7:00 am |
RNS |
Total Voting Rights |
| 29th Mar 2016 8:00 am |
RNS |
Director/PDMR Shareholding |
| 23rd Mar 2016 10:34 am |
RNS |
Holding(s) in Company |
| 22nd Mar 2016 2:00 pm |
RNS |
Closing of U.S. Public Offering of ADSs |
| 21st Mar 2016 8:54 am |
RNS |
Director/PDMR Shareholding |
| 21st Mar 2016 7:00 am |
RNS |
Sulfatinib Phase III registration study |
| 18th Mar 2016 4:18 pm |
RNS |
Final Prospectus |
| 17th Mar 2016 7:00 am |
RNS |
Pricing of U.S. Public Offering of ADSs |
| 15th Mar 2016 7:00 am |
RNS |
2015 Annual Report and Notice of AGM |
| 7th Mar 2016 7:59 am |
RNS |
Fifth Filing of Form F-1 Registration Statement |
| 4th Mar 2016 6:12 pm |
RNS |
Launch of Potential U.S. Public Offering of ADSs |
| 4th Mar 2016 5:54 pm |
RNS |
Fifth Filing of Form F-1 Registration Statement |
| 2nd Mar 2016 7:00 am |
RNS |
Sulfatinib Phase II initation in thyroid cancer |
| 1st Mar 2016 4:29 pm |
RNS |
Fourth Filing of Form F-1 Registration Statement |
| 1st Mar 2016 7:00 am |
RNS |
Final Results |
| 11th Feb 2016 5:39 pm |
RNS |
Public Filing of Form F-1 Registration Statement |
| 29th Jan 2016 8:03 am |
RNS |
Notice of Results |
| 15th Jan 2016 7:02 am |
RNS |
Chi-Med initiates HMPL-523 Phase I clinical trial |
| 29th Dec 2015 7:43 am |
RNS |
Blocklisting Six Monthly Return |
| 18th Dec 2015 7:00 am |
RNS |
Initiation sulfatinib Phase III registration study |
| 9th Dec 2015 7:00 am |
RNS |
US$105 m Shanghai land compensation agreement |
| 8th Dec 2015 7:00 am |
RNS |
Initiation of fruquintinib Phase 3 trial in NSCLC |
| 13th Nov 2015 2:50 pm |
RNS |
Second Public Filing of Registration Statement |
| 10th Nov 2015 1:13 pm |
RNS |
Results of Extraordinary General Meeting |
| 9th Nov 2015 7:59 am |
RNS |
Director/PDMR Shareholding |
| 6th Nov 2015 7:00 am |
RNS |
Chi-Med initiates sulfatinib U.S. clinical trials |
| 30th Oct 2015 7:00 am |
RNS |
Clinical results presented |
| 30th Oct 2015 7:00 am |
RNS |
Total Voting Rights |
| 30th Oct 2015 7:00 am |
RNS |
Completion of Phase I clinical trial of HMPL 523 |
| 20th Oct 2015 2:40 pm |
RNS |
Director's Share Dealing |
| 19th Oct 2015 7:00 am |
RNS |
Awards under Long Term Incentive Plan |
| 16th Oct 2015 12:17 pm |
RNS |
Shareholders' Circular and Notice of EGM |
| 16th Oct 2015 12:15 pm |
RNS |
Filing of Registration Statement on Form F1 |
| 16th Oct 2015 12:03 pm |
RNS |
Chi-Med files Nasdaq Registration Statement |
| 13th Oct 2015 7:00 am |
RNS |
Enrolment complete in Savolitinib Phase II trial |
| 12th Oct 2015 2:09 pm |
RNS |
Holding(s) in Company |
